|
Digilab BioVisioN GmbH Closes Cooperation Agreement With Boehringer Ingelheim |
|
|
|
09 Mar 2006 |
HANNOVER, Germany | Mar 08, 2006 | Hanover-based Digilab BioVisioN GmbH announces closing of a cooperation contract with Boehringer Ingelheim Pharma GmbH & Co. KG. This is the first collaboration contract of the company that takes over commercial activities from BioVisioN AG within a reorganization process.
Within the project Digilab BioVisioN will analyze the quantitative peptide content of biological samples for the German pharmaceutical company. Using the patent-protected Peptidomics(R)-Technologies of Digilab BioVisioN, differences in peptide patterns are sought in order to identify new biomarkers. Further details of the project were not released.
Dr. Rainer Voegeli, Chief Business Officer, states: ,,We are pleased that a renowned pharmaceutical company like Boehringer Ingelheim starts a new project with us during the ongoing reorganization, giving us a confirmation of the relevance of our technology."
BioVisioN was founded in 1997 and has currently 45 employees at its seat in Hanover/Germany. Digilab BioVisioN is specialized on the quantitative analysis of the entire peptidome (all peptides and small proteins of a sample) of biological samples using its proprietary Peptidomics-technologies for the discovery of biomarkers.
SOURCE: Digilab BioVisioN GmbH |
